GT
Gyala Therapeutics develops CAR T cell therapies targeting CD19 and BCMA for the treatment of hematological malignancies, including leukemia. Their approach utilizes modified lymphocytes to enhance the immune response against cancers with significant clinical unmet needs.
Updated 20 months ago
Funding
$3.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CI
Funding rounds are not available yet.
Founders
Product
Features
- Gyala Therapeutics develops CAR T cell therapies targeting CD19 and BCMA for the treatment of hematological malignancies, including leukemia. Their approach utilizes modified lymphocytes to enhance the immune response against cancers with significant clinical unmet needs.